Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
Institutional and Insider Ownership
4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for Nurix Therapeutics and Valion Bio, Inc. Common Stock, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Nurix Therapeutics and Valion Bio, Inc. Common Stock”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $83.98 million | 27.35 | -$264.46 million | ($3.45) | -6.41 |
| Valion Bio, Inc. Common Stock | $780,000.00 | 1.77 | -$8.88 million | ($159.25) | -0.01 |
Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nurix Therapeutics and Valion Bio, Inc. Common Stock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | 42.01% | 62.20% | 47.57% |
| Valion Bio, Inc. Common Stock | N/A | -193.17% | -67.10% |
Risk and Volatility
Nurix Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Summary
Nurix Therapeutics beats Valion Bio, Inc. Common Stock on 11 of the 14 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
